863725-39-7

Basic information

• Product Name: (R)-pulegone dibromide
• Synonyms: (R)-pulegone dibromide
• CAS NO: 863725-39-7
• Molecular Weight: 312.044
• Mol File: 863725-39-7.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: (R)-pulegone dibromide(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-pulegone dibromide(863725-39-7)
• EPA Substance Registry System: (R)-pulegone dibromide(863725-39-7)

Safety Data

• Hazardous Substances Data: 863725-39-7(Hazardous Substances Data)

Upstream product

• 89-82-7 pulegone 

Downstream Products

• 623935-92-2 ethyl (2R)-2-methyl-5-(propan-2-ylidene)cyclopentanecarboxylate 
• 1001180-49-9 tert-butyl 4-((5R,7S)-5-methyl-7-((4-nitrobenzoyl)oxy)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-piperazine-1-carboxylate 
• 1001180-47-7 tert-butyl 4-((5R,7R)-5-methyl-7-((4-nitrobenzoyl)oxy)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-piperazine-1-carboxylate 
• 1001201-61-1 tert-butyl 4-((5R,7S)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine-1-carboxylate 

Relevant articles and documents

Pheromone synthesis. Part 264: Synthesis of the core 3-oxabicyclo[3.3.0]octane structures of gomadalactones A, B and C, the components of the contact sex pheromone of the white-spotted longicorn beetle, Anoplophora malasiaca

The core bicyclic cyclopentanelactone structures of gomadalactones A, B and C with α-hydroxyketone system were synthesized from (R)-pulegone, employing deconjugation of an α,β-unsaturated lactone as the key step. Comparison of the CD spectra of the synthetic compounds with those of the natural products confirmed the absolute configuration of the natural pheromone components as proposed in 2007. X-ray crystallographic analysis of the model compound of gomadalactone B core structure was carried out.

PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS

The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invent

CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS

The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Formula (I). Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.